The main objective of this study is to see if repeat subcutaneous doses of dupilumab, the study medicine, helps to reduce eosinophilic inflammation in the stomach of participants with eosinophilic gastritis/ eosinophilic gastroenteritis compared to a placebo. A placebo is a pill or substance that is given to a patient like a drug but that has no physical effect on the patient.